FDA Approves First-of-Its-Kind Pancreatic Cancer Drug Six Months Early
The US FDA granted expedited approval on August 26, 2026, to daraxonrasib — sold under the brand name Rasonque by Revolution Medicines — as the first targeted therapy of its kind for metastatic pancreatic cancer. The agency acted more than six months ahead of its target date, capping a fast-moving regulatory path that included a New Drug Application accepted in July 2026, a national priority voucher granted in October 2025, and a prior Breakthrough Therapy designation. Acting FDA Commissioner Kyle Diamantas oversaw the approval The Guardian FDA.
Daraxonrasib, also known as RMC-6236, is a pill that works by blocking a mutated protein called Kras, which drives tumor growth in more than 90% of pancreatic cancer cases. Kras is part of the Ras gene family, long understood to play a central role in cancer since the 1980s. The drug uses what scientists call a "molecular glue" mechanism — essentially a compound that helps the drug stick to the protein — to bind with multiple Kras subtypes. Until now, Kras proteins were considered essentially undruggable because their smooth, flat structure lacked the deep pockets that traditional drugs typically latch onto FDA The Guardian FDA.
The clinical evidence comes from a company-funded study of 500 patients whose metastatic pancreatic cancer had stopped responding to prior treatment. Patients taking daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving chemotherapy — nearly double the survival time, with fewer severe side effects The Guardian.
These results arrive against a grim epidemiological backdrop. The American Cancer Society estimates roughly 67,000 new pancreatic cancer cases will be diagnosed in the US this year, with more than 52,000 deaths. The five-year overall survival rate stands at 13% The Guardian.
Public interest in daraxonrasib surged before official approval, prompting the FDA to permit expanded access for patients meeting certain criteria. Former US Senator Ben Sasse of Nebraska described on CBS's 60 Minutes how he experienced less pain while taking the drug. Revolution Medicines, based in Redwood City, California, is also studying its molecular glue technology for other forms of cancer, including lung cancer. Daraxonrasib holds FDA orphan drug designation for pancreatic cancer treatment The Guardian FDA.
The broader context here is the pharmaceutical industry's sustained effort to drug a target that resisted decades of research. The Ras gene family's role in cancer has been understood since the 1980s, yet the structural biology of Kras proteins — lacking the deep binding pockets that traditional drugs exploit — made them pharmacologically intractable. Revolution Medicines' molecular glue approach circumvents that obstacle by using a different way of binding to the protein. If the mechanism proves durable across Kras subtypes in other cancer types, the platform could reshape treatment for Ras-driven cancers beyond the pancreas.
Several factors merit attention as daraxonrasib enters clinical practice. The trial enrolled patients whose disease had progressed after prior treatment, leaving open questions about how well the drug works in earlier treatment stages. The 13.2-month median overall survival, while a meaningful improvement over the chemotherapy control arm, must be weighed against how long responses last and whether resistance pathways — a common problem with targeted therapies — will emerge. The company-funded nature of the pivotal trial also warrants consideration; independent confirmation and real-world evidence will clarify whether the survival benefit holds outside controlled study protocols. The FDA's decision to grant expanded access before approval signals both the urgency of the unmet need and the political pressure surrounding terminal pancreatic cancer patients with limited options.
For oncologists treating metastatic pancreatic cancer, daraxonrasib introduces a new therapeutic class into a disease where standard treatments have yielded only incremental gains. The drug's safety profile — fewer severe side effects relative to chemotherapy — may improve treatment adherence and quality of life, factors of particular concern in a disease setting that borders on palliative care. How payers price Rasonque and what access restrictions emerge will shape its practical reach. Revolution Medicines' parallel development of its molecular glue platform in lung cancer and other Ras-driven tumors will be closely watched as an indicator of whether this mechanism proves useful beyond a single cancer type.
